A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were ...

It closed up by 14 percent on Thursday, adding $100 billion to the ... which sells its drug as Zepbound for obesity and Mounjaro for diabetes, and Novo Nordisk, which sells its medicine as Wegovy ...

A line chart showing valuation multiples Novo Nordisk’s fortunes turned ... details of a trial of its obesity pill orforglipron which added $100 billion to its market value.

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

Following the initial Food and Drug Administration (FDA ... This opens the door for Novo Nordisk to serve over 100 million patients in the booming local diabetes and obesity market, acting ...

European shares ended slightly higher on Tuesday on the back of rising financials and post-earnings gains in L'Oreal, though ...

In return, Novo Nordisk will receive exclusive, worldwide rights for the drug in all indications ... Lexicon does owe $100.298 million in long-term debt. Looking at cash flows, Lexicon utilized ...